Sign Up And Receive Our Latest Promotions!
.svg){kind=small}
discovery unity
Accelerating R&D and laying the foundation of Digital Precision Medicine
in Pharma & Life Sciences
Data Collection
Discovery UNITY is a multimodality platform that supports multiple types of images and formats.
Compatible formats today (continuously expanding):
- Industry standard DICOM,
- Device-Specific formats
- and non-medical images (PNG, JEPG, TIFF, PDF).
Image types supported today (continuously expanding):
- OCT (cube, cross, radial, line)
- Fundus
- Color Fundus
Data processing & visualization
- First, data is organized, harmonized and aggregated into a single ecosystem.
- Then data is analysed at scale using artificial intelligence to extract insights about disease progression, treatment outcomes and patient progression prediction.
Data Collaboration
Participative research is enabled across the organization and with external experts globally using secure, cloud-based access to data anytime from anywhere, with insights from both certified and validated research modules for analysis.
Discovery UNITY is an organization’s:
Single data platform to manage data from different sources and devices, at scale. Access data anytime from anywhere.
Integrated AI technology to extract insights across datasets for a better understanding of diseases and patient groups.
A data insurance policy. Secured storage and archival only accessible to authorized personnel to provide peace-of-mind to an organization’s precious resource, its data.
.webp)
CHALLENGES
INCREASED TIME & RISK: pharma pipelines from discovery to launch can take an average of 10-12 years, at an average cost of $2.6B. Significant risk is undertaken as only an average of 1 compound out of 10,000 is introduced to the market.
COMPETITION FOR PATIENT POPULATIONS: Therapies targeting similar pathways limit the market potential and the opportunity to personalize therapy with more well-defined assessment criteria.
SOLUTION
R&D pipeline time and costs can be reduced by leveraging Discovery UNITY features:
- clinical research workflows (grading surveys and feedback collection for collaborative and independent data review)
- multimodal data management analysis
- AI models for analysis in wet and dry AMD, Diabetic Retinopathy and Macular Edema, Retinal Vein Occlusion, Geographic Atrophy and Glaucoma.
RESULT
From a standard analysis workflow of 6 months to 6 weeks reduction of both time and cost of research workflows for a study of >15,000 OCTs
Interested in learning more?
*Disclaimer
RetinAI Discovery® platform, RetinAI OCT Atlas® and Macula Biomarkers, as well as LuxIA® (Diabetic Retinopathy Screening model) are CE-marked medical devices in accordance with the Medical Devices Regulation (EU) 2017/745 (CE2797). RetinAI Discovery® platform is also a medical device cleared for clinical use by the FDA. The AI modules for biomarkers, fluid, and layer segmentation and quantification in retinal pathologies are designated as Research Use Only (RUO) in the USA. Please be advised that these tools are not intended to replace professional medical advice, diagnosis, or treatment. We do not warrant or guarantee the clinical accuracy, completeness, or usefulness of any content provided by RUO products. For more information, please read our Privacy Notice (https://www.retinai.com/privacy-policy) and Data Processing Agreement (https://www.retinai.com/data-processing-agreement).
RetinAI Discovery® and RetinAI® are trademarks of Ikerian AG.
